Cytovia Therapeutics appointed Wei Li as acting chief scientific officer. Li was most recently chief development officer at Korean biotech OliX Pharmaceuticals. Her prior experience includes more than a decade at cancer drug developer Boston Biomedical, where she led development of the company’s lead drug candidate.
New York-based Cytovia is developing cancer immunotherapies based on natural killer cells, a type of immune cell. The company plans to start multiple clinical trials of its “off-the-shelf” treatments in 2021.